Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands

David R.J. Owen, Roger N. Gunn, Eugenii A. Rabiner, Idriss Bennacef, Masahiro Fujita, William C. Kreisl, Robert B. Innis, Victor W. Pike, Richard Reynolds, Paul M. Matthews and Christine A. Parker
Journal of Nuclear Medicine January 2011, 52 (1) 24-32; DOI: https://doi.org/10.2967/jnumed.110.079459
David R.J. Owen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger N. Gunn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugenii A. Rabiner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Idriss Bennacef
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiro Fujita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William C. Kreisl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert B. Innis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor W. Pike
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Reynolds
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul M. Matthews
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine A. Parker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Competition assay with 3H-PK11195 and unlabeled PBR28, using tissue from donors with no history of neurologic disease. Each data point represents mean value of all subjects, and error bars represent SEM. Conc = concentration.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Competition assays with 3H-PK11195 and unlabeled TSPO ligand using brain tissue previously characterized as HAB, LAB, or MAB by PBR28 assays. Each data point represents mean value of at least 4 subjects, and error bars represent SEM. (A) Phenoxyphenyl acetamide derivatives. (B) Bicyclic linker derivatives. (C) Phenyl–isoquinolinecarboxamide derivatives. Conc = concentration; SB = specific binding.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Competition assays with 3H-PK11195 and unlabeled PBR111 in presence or absence of PBR28 (50 nM).

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    11C- PBR28 PET data from 32 healthy volunteers expressed as histogram with mixture model analysis showing 2 distributions for each measurement. (A) Volume of distribution. (B) Plasma free fraction. (C) Volume of distribution/plasma free fraction. Blue curves denote single-component solutions, and green and black curves denote 2-component solutions. For 2-component solutions, whereas different individuals are within each gaussian group (e.g., green) for 3 parameters, there was good agreement between A and B (74%) and A and C (66%).

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    TSPO ligands displayed in structural classes.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Competition Binding Studies with PK11195, PBR28, PBR06, PBR111, DPA713, and DAA1106

    Ki (nM) of…
    Binding classPK11195*PBR28*PBR06DPA713DAA1106PBR111
    HABs28.3 ± 4.0 (n = 6)3.4 ± 0.2 (n = 6)8.6 ± 2.0 (n = 5)15.0 ± 2.2 (n = 5)2.8 ± 0.3 (n = 4)15.6 ± 3.7 (n = 5)
    LABs22.3 ± 2.2 (n = 5)188 ± 7.0 (n = 5)149 ± 46.6 (n = 4)66.4 ± 7.8 (n = 4)13.1 ± 1.3 (n = 4)61.8 ± 10.7 (n = 5)
    MABs23.6 ± 5.5 (n = 4)Two receptors detected (n = 4): 4.0 ± 1.2 (high) and 313 ± 38 (low)Two receptors detected (n = 4): 13.4 ± 3.4 (high) and 176 ± 103 (low)26.8 ± 2.9 (n = 4)4.8 ± 0.4 (n = 4)30.3 ± 4.1 (n = 4)
    Ki ratio of LAB to HAB0.855174.44.74.0
    t test
     HAB vs. LABP < 0.25P < 0.0001P < 0.011P < 0.001P < 0.001P < 0.003
     MAB vs. LABP < 0.82NANAP < 0.003P < 0.001P < 0.04
     MAB vs. HABP < 0.50NANAP < 0.01P < 0.005P < 0.03
    • ↵* Data reproduced from Owen et al. (6).

    • NA = not applicable.

    • Data are expressed as mean ± SEM. All data in Table 1 were generated from donors B1–B15, inclusive.

    • View popup
    TABLE 2

    Competition Binding Studies with PBR111 in Absence and Presence of 50 nM of PBR28

    Ki (nM) of…Reduction (%) in specific signal after block with PBR28 (50 nM)
    Binding classPBR111PBR111 after block with PBR28 (50 nM)
    HABs15.6 ± 3.7 (n = 5)Not measurable69.0 ± 4.6 (n = 4)
    LABs61.8 ± 10.7 (n = 5)51.7 ± 12.2 (n = 4)21.2 ± 4.8 (n = 4)
    MABs30.3 ± 4.1 (n = 4)54.4 ± 5.3 (n = 4)49.3 ± 2.9 (n = 4)
    t test
     HAB vs LABP < 0.003NAP < 0.0004
     MAB vs LABP < 0.04P < 0.84P < 0.002
     MAB vs HABP < 0.03NAP < 0.01
    • NA = not applicable.

    • Data are expressed as mean ± SEM.

    • View popup
    TABLE 3

    Ratio of Specific Signal for HABs, MABs, and LABs with Different TSPO Ligands

    LigandLABMABHAB
    PBR28128.255.3
    PBR0619.217.3
    DAA110612.94.7
    PBR11112.54.0
    DPA17312.74.4
    PK1119510.90.8
    • MABs are assumed to express equal number of HAB and MAB sites. Receptor density is assumed to remain constant. Values are calculated as BPND relative to BPND of LABs.

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 52 (1)
Journal of Nuclear Medicine
Vol. 52, Issue 1
January 1, 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands
David R.J. Owen, Roger N. Gunn, Eugenii A. Rabiner, Idriss Bennacef, Masahiro Fujita, William C. Kreisl, Robert B. Innis, Victor W. Pike, Richard Reynolds, Paul M. Matthews, Christine A. Parker
Journal of Nuclear Medicine Jan 2011, 52 (1) 24-32; DOI: 10.2967/jnumed.110.079459

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands
David R.J. Owen, Roger N. Gunn, Eugenii A. Rabiner, Idriss Bennacef, Masahiro Fujita, William C. Kreisl, Robert B. Innis, Victor W. Pike, Richard Reynolds, Paul M. Matthews, Christine A. Parker
Journal of Nuclear Medicine Jan 2011, 52 (1) 24-32; DOI: 10.2967/jnumed.110.079459
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Individual regional associations between A{beta}-, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies
  • Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis: A Retrospective Study
  • Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant
  • Mapping microglia and astrocytes activation in vivo using diffusion MRI
  • [11C]PK11195-PET Brain Imaging of the Mitochondrial Translocator Protein in Mitochondrial Disease
  • Neuroinflammation in cognitive decline post-cardiac surgery (the FOCUS study): an observational study protocol
  • Structural and Clinical Correlates of a Periventricular Gradient of Neuroinflammation in Multiple Sclerosis
  • Quantification of Macrophage-Driven Inflammation During Myocardial Infarction with 18F-LW223, a Novel TSPO Radiotracer with Binding Independent of the rs6971 Human Polymorphism
  • In vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies
  • Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study
  • Translocator Protein Ligand Protects against Neurodegeneration in the MPTP Mouse Model of Parkinsonism
  • PET studies of the glial cell marker TSPO in psychosis patients - a meta-analysis using individual participant data
  • Parametric Binding Images of the TSPO Ligand 18F-DPA-714
  • Pharmacokinetic Analysis of 11C-PBR28 in the Rat Model of Herpes Encephalitis: Comparison with (R)-11C-PK11195
  • Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases?
  • Structure of the mammalian TSPO/PBR protein
  • Optimized Quantification of Translocator Protein Radioligand 18F-DPA-714 Uptake in the Brain of Genotyped Healthy Volunteers
  • Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein
  • In Vivo Quantification of Cerebral Translocator Protein Binding in Humans Using 6-Chloro-2-(4'-123I-Iodophenyl)-3-(N,N-Diethyl)-Imidazo[1,2-a]Pyridine-3-Acetamide SPECT
  • New Targets for the Development of PET Tracers for Imaging Neurodegeneration in Alzheimer Disease
  • Structure of the Mitochondrial Translocator Protein in Complex with a Diagnostic Ligand
  • Quantification of the Specific Translocator Protein Signal of 18F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding
  • Influence of TSPO Genotype on 11C-PBR28 Standardized Uptake Values
  • Radiation Dosimetry and Biodistribution of the TSPO Ligand 11C-DPA-713 in Humans
  • The Translocator Protein
  • Google Scholar

More in this TOC Section

  • First-in-Human Study of 18F-Labeled PET Tracer for Glutamate AMPA Receptor [18F]K-40: A Derivative of [11C]K-2
  • Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis
  • [11C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study
Show more Clinical Investigation

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire